tetano
Editor, Senior Moderator
Vaccine
. 2021 Dec 24;S0264-410X(21)01654-6.
doi: 10.1016/j.vaccine.2021.12.044. Online ahead of print.
Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents
Young June Choe[SUP] 1 [/SUP], Seonju Yi[SUP] 2 [/SUP], Insob Hwang[SUP] 2 [/SUP], Jia Kim[SUP] 2 [/SUP], Young-Joon Park[SUP] 2 [/SUP], Eunhee Cho[SUP] 2 [/SUP], Myoungyoun Jo[SUP] 3 [/SUP], Hyunju Lee[SUP] 4 [/SUP], Eun Hwa Choi[SUP] 5 [/SUP]
Affiliations
Abstract
In South Korea, all 12th grade students (highs school seniors) were offered BNT162b2 vaccine starting July 19, 2021; while 10[SUP]th[/SUP]-11th grade students were not eligible. We conducted a nationwide retrospective cohort study by to determine the safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents against SARS-CoV-2 infection. Among 444,313 persons who received the first dose of vaccine, reporting rate for myocarditis and/or pericarditis was 1.8 per 100,000 (95% C.I. 0.8-3.5) among first-dose recipients and 4.3 per 100,000 (95% C.I. 2.6-6.7) in second-dose recipients. Vaccine effectiveness against symptomatic/asymptomatic SARS-CoV-2 infection 14 days post-first dose vaccination was 91.1% (95% C.I. 89.6-92.5), and 14 days post-second dose was 99.1% (95% C.I. 98.5-99.5). In this retrospective cohort study, BNT162b2 vaccination was safe and was associated with a significantly lower risk of SARS-CoV-2 infection, suggesting that vaccination in adolescent may reduce the burden of Covid-19.
Keywords: Adolescent; Coronavirus disease 2019; Covid-19; SARS-CoV-2; Vaccination; Vaccine.
. 2021 Dec 24;S0264-410X(21)01654-6.
doi: 10.1016/j.vaccine.2021.12.044. Online ahead of print.
Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents
Young June Choe[SUP] 1 [/SUP], Seonju Yi[SUP] 2 [/SUP], Insob Hwang[SUP] 2 [/SUP], Jia Kim[SUP] 2 [/SUP], Young-Joon Park[SUP] 2 [/SUP], Eunhee Cho[SUP] 2 [/SUP], Myoungyoun Jo[SUP] 3 [/SUP], Hyunju Lee[SUP] 4 [/SUP], Eun Hwa Choi[SUP] 5 [/SUP]
Affiliations
- PMID: 35012777
- DOI: 10.1016/j.vaccine.2021.12.044
Abstract
In South Korea, all 12th grade students (highs school seniors) were offered BNT162b2 vaccine starting July 19, 2021; while 10[SUP]th[/SUP]-11th grade students were not eligible. We conducted a nationwide retrospective cohort study by to determine the safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents against SARS-CoV-2 infection. Among 444,313 persons who received the first dose of vaccine, reporting rate for myocarditis and/or pericarditis was 1.8 per 100,000 (95% C.I. 0.8-3.5) among first-dose recipients and 4.3 per 100,000 (95% C.I. 2.6-6.7) in second-dose recipients. Vaccine effectiveness against symptomatic/asymptomatic SARS-CoV-2 infection 14 days post-first dose vaccination was 91.1% (95% C.I. 89.6-92.5), and 14 days post-second dose was 99.1% (95% C.I. 98.5-99.5). In this retrospective cohort study, BNT162b2 vaccination was safe and was associated with a significantly lower risk of SARS-CoV-2 infection, suggesting that vaccination in adolescent may reduce the burden of Covid-19.
Keywords: Adolescent; Coronavirus disease 2019; Covid-19; SARS-CoV-2; Vaccination; Vaccine.